NEXTVIVO
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and tested in immune-competent human-derived models.
NEXTVIVO
Industry:
Biotechnology
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.nextvivo.bio
Status:
Active
Total Funding:
7.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Accellix
Accellix is an assay delivery platform
Arch Oncology
Arch Oncology is an immuno-oncology company
BioCompatibility Innovation
Biocompatibility Innovation operates in the biomedical and biotechnology fields.
CH-Bioforce Oy
CH-Bioforce is the developer of the best biomass fractionation technology in the world.
CleanSpot
CleanSpot, Inc is a leading developer of antimicrobial coatings technology.
CO2 Solutions
Nature's Power for Carbon Capture / La puissance de la nature pour la capture du carbone.
Decoy Smart Control
Decoy Smart Control is biological solutions developer for pest control.
Dinfectome
Dinfectome researches and develops molecular detection technology.
Feldan Therapeutics
Feldan Therapeutics has developed a patented peptide-based technology platform.
Feroka
FEROKA is developing transdermal drug delivery system solutions with multi-layer microneedle, quick-dissolving and 3D printing technology
Gennady Nikitin
Gennady Nikitin is a metabolic anti-cancer drug screening platform
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Karma Biotechnologies
Karma Biotechnologies is solving autoimmunity, allergies, and food sensitivities with our Xavineâ„¢ precision immunotherapy platform.
Miraca Life Sciences
Miraca Life Sciences provides pathology services like dermatopathology, breast pathology, gastroenterology.
Nexion Biosciences Inc.
Nexion Biosciences Inc. offers and delivers robust pre-field trial opportunities that is supported with statistical validation.
Proteomics International
Proteomics International is a pioneering medical technology company.
Quantum Diamond Technologies
Quantum Diamond Technologies develops ultrasensitive biomaterial detection and diagnostics platform.
Saniona
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
SEED Biosciences
SEED is a spinoff from the Swiss Federal Institute of Technology.
SN BioScience
SN BioScience is developing cutting-edge platform technology.
Tecan
Tecan is a global provider of automated laboratory instruments and solutions.
VastCon
VastCon Inc. is a biotech company developing early screening and diagnostics for cancer.
Vetbiobank
Vetbiobank is a biotech company specialized in veterinary regenerative medicine.
Vox Biomedical
Vox Biomedical is a diagnostics company developing an innovative breath analyzer.
Current Employees Featured
Adam Margolin CEO @ NextVivo
CEO
Investors List
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati investment in Seed Round - NextVivo
Alexandria Venture Investments
Alexandria Venture Investments investment in Seed Round - NextVivo
Khosla Ventures
Khosla Ventures investment in Seed Round - NextVivo
Official Site Inspections
http://www.nextvivo.bio Semrush global rank: 5.16 M Semrush visits lastest month: 1.57 K
- Host name: 104.21.54.19
- IP address: 104.21.54.19
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NextVivo"
NextVivo | About NextVivo
Dec 7, 2023 · We are a team of scientists and dreamers who share a set of values to promote an enabling, transparent, team oriented, mission driven culture. We all want to change the world …See details»
NextVivo | Immune Organoid Technology
NextVivo’s organoids provide 3D holistic models of healthy and disease tissue that retain all key immune cell types and their functional interactions. Learn More. nextSee details»
NextVivo - Crunchbase Company Profile & Funding
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and …See details»
NextVivo Company Profile 2024: Valuation, Funding & Investors
Developer of an immune organoid technology intended to generate human cell and antibody candidate therapies by leveraging the immune system's natural defenses.See details»
NextVivo | Applications
By leveraging NextVivo’s lymphoid organoid technology we aim to create an efficient, high fidelity platform for generating fully human therapeutic antibodies with improved safety and efficacy against a broad range of therapeutic targets.See details»
NextVivo - Org Chart, Teams, Culture & Jobs - The Org
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more …See details»
NextVivo - LinkedIn
NextVivo is an ambitious start-up company, located in Stanford Research Park. We are working to leverage the power of the breakthrough technology of human derived immune organoids, …See details»
NextVivo Launches from Khosla Ventures to Transform Drug …
Dec 9, 2021 · NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate development …See details»
NextVivo Company Profile - Office Locations, Competitors ... - Craft
NextVivo is a biotech company that develops an immune organoid technology platform for drug development. It accelerates the development of therapies that are generated and tested in …See details»
NextVivo - workinbiotech.com
NextVivo's lymphoid platform aims to generate fully human therapeutic antibodies with improved safety and efficacy. Using the patient’s own immune cells and their tumor organoids, NextVivo …See details»
NextVivo, Inc. Company Profile | Palo Alto, CA | Competitors ...
Find company research, competitor information, contact details & financial data for NextVivo, Inc. of Palo Alto, CA. Get the latest business insights from Dun & Bradstreet.See details»
Development Using Next-Generation Organoid Platform NextVivo …
NextVivo Launches from Khosla Ventures to Transform Drug Development Using Next-Generation Organoid Platform - Company Raises $7.9 Million in Financing led by Khosla …See details»
NextVivo Launches from Khosla Ventures to Transform Drug …
Dec 9, 2021 · NextVivo, a biotech company developing an immune organoid technology platform, emerged from stealth today with $7.9M in financing led by Khosla Ventures, with participation …See details»
Khosla Ventures Leads Seed Financing for Biotech Startup NextVivo
Dec 9, 2021 · Khosla Ventures is betting that a new means of replicating human biology in the lab will enable startup NextVivo Inc. to develop novel disease treatments.See details»
NextVivo Launches from Khosla Ventures to Transform Drug
Dec 9, 2021 · NextVivo , a biotech company developing an immune organoid technology platform, emerged from stealth today with $7.9M in financing led by Khosla Ventures, with participation …See details»
Contact Us - NextVivo
Want to learn more about NextVivo? We look forward to discussing partnership and investment opportunities with you. Fill out our form or email us at info@nextvivo.bio and we’ll be in touch …See details»
Immune Organoid Platform Company NextVivo Raises $7.9 Million …
Dec 24, 2021 · NextVivo — a biotech company developing an immune organoid technology platform — emerged from stealth recently with $7.9 million in financing led by Khosla …See details»
NextVivo | Technology
NextVivo tumor organoids grow all key immune cells in the tumor microenvironment. ALI technology enables creation of organoids that retain the complex physiological spatial …See details»
NextVivo Raises $7.9M in Financing - FinSMEs
Dec 10, 2021 · NextVivo, a Palo Alto, Calif.-based biotech company developing an immune organoid technology platform, emerged from stealth with $7.9M in financing. The round was …See details»
Khosla Ventures Leads Seed Financing for Biotech Startup
Khosla has led a $7.9 million seed investment in Palo Alto, Calif.-based NextVivo, which says its technology enables it to grow three-dimensional human tissue in the lab better than has been …See details»